Annapolis-based biodefense firm PharmAthene has been awarded an $83.9 million multiyear contract from the National Institutes of Health to develop and advance anthrax vaccine.

The company’s work will focus on a vaccine that can be stored and used without the need for cold temperatures and that requires fewer doses to achieve immunity.